1. Half dose ChAdOx1 nCoV-19 vaccine was equivalent to full doses to reduce moderate and severe COVID-19 cases.
- Author
-
Galvão-Lima LJ, de Medeiros Júnior NF, Jesus GS, Morais AHF, Caldeira-Silva GJP, Queiroz Dos Santos JP, Rocha M, Marques Dos Santos M, Freire PA, Silva RD, Gouvea MDPG, Neto LFP, Domingues CMAS, Teixeira-Carvalho A, Martins-Filho OA, Valim V, and Valentim RAM
- Abstract
Objectives: Previously, we presented the effectiveness of ChAdOx1 nCoV-19 half-dose (HD) immunization for preventing new COVID-19 cases. Here, we evaluated the administration of an HD of ChAdOx1 nCoV-19 in the primary immunization protocol (up to two doses) in reducing moderate and severe cases, hospitalizations, and deaths when compared to the administration of full doses (FD) after a long-term follow-up., Methods: We evaluated data from 29,469 participants between January 2021 and November 2022 who received an HD or FD vaccine and crossed this information with their medical records to identify those who developed moderate or severe cases. All participants were classified into four groups according to their immunization status and followed 500 days after the last vaccine administration., Results: The propensity-score matching analysis indicates that the administration of the two HDs of ChAdOx1 nCoV-19 was equivalent to the use of two FDs to reduce moderate and severe COVID-19 cases. The relative risk of being infected and developing moderate or severe conditions after the administration of at least one HD or FD was similar 150 or 500 days after the administration of the immunizers., Conclusion: Administering two HDs can be used safely as a cost-effective alternative to the primary immunization protocol., Competing Interests: The authors have no competing interests to declare., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF